Mirvetuximab Soravtansine Approved by NICE for NHS
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Mirvetuximab soravtansine approved by NICE for NHS use, becoming the first new therapy for hard‑to‑treat ovarian cancer in 20 years.
- Mirvetuximab soravtansine extends median overall survival from 12.8 months on standard chemotherapy to 16.5 months.
- Mirvetuximab soravtansine reduces side effects, allowing patients to keep their hair, experience less fatigue, and receive infusions every three weeks instead of weekly.
- Patricia Hill (64, north London) started the drug in January and says it lets her attend West End shows, dine out, and visit family, describing it as a “game changer”.
- Jenny Green (71, Hertfordshire) participated in the clinical trials, reports minimal side effects and tumor shrinkage, and says her blood tests have returned to normal ranges.
Why it matters: Up to 400 English ovarian‑cancer patients per year will receive a longer, more tolerable therapy, adding ~3.7 months of median survival and reducing side‑effects, which eases patient burden and improves quality of life.
